NL1010018C2 - Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. - Google Patents
Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. Download PDFInfo
- Publication number
- NL1010018C2 NL1010018C2 NL1010018A NL1010018A NL1010018C2 NL 1010018 C2 NL1010018 C2 NL 1010018C2 NL 1010018 A NL1010018 A NL 1010018A NL 1010018 A NL1010018 A NL 1010018A NL 1010018 C2 NL1010018 C2 NL 1010018C2
- Authority
- NL
- Netherlands
- Prior art keywords
- alkyl
- formula
- ethyl
- group
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202762 | 1997-09-09 | ||
| EP97202762 | 1997-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL1010018C2 true NL1010018C2 (nl) | 1999-03-10 |
Family
ID=8228716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL1010018A NL1010018C2 (nl) | 1997-09-09 | 1998-09-04 | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6350750B1 (fr) |
| EP (1) | EP0966442B1 (fr) |
| JP (1) | JP4276703B2 (fr) |
| AT (1) | ATE348812T1 (fr) |
| AU (1) | AU9624198A (fr) |
| CA (1) | CA2270777C (fr) |
| DE (1) | DE69836678T2 (fr) |
| NL (1) | NL1010018C2 (fr) |
| WO (1) | WO1999012908A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000069311A (ko) * | 1997-04-22 | 2000-11-25 | 디르크 반테 | Ｃｒｆ 길항성 퀴노- 및 퀴나졸린 |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| WO2001023389A2 (fr) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | Hétérocycles à substitution alkylène-diamine |
| AU2001234180A1 (en) * | 2000-02-25 | 2001-09-03 | Japan Tobacco Inc. | Benzamide derivative and use thereof |
| US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
| KR20110010824A (ko) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료 |
| JP4920410B2 (ja) * | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
| JP2007501821A (ja) * | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
| WO2005013997A1 (fr) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf) |
| EP3378854B1 (fr) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels |
| US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| WO2018151873A1 (fr) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| EP3781565A1 (fr) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-méthyl-aza-quinazolines |
| EP4223761A1 (fr) * | 2020-09-30 | 2023-08-09 | Shanghai Pharmaceuticals Holding Co., Ltd. | Composé quinazoline et son application |
| TW202337890A (zh) * | 2021-04-30 | 2023-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 橋環類化合物、其製備方法及其在醫藥上的應用 |
| CN115504932B (zh) * | 2022-08-12 | 2024-01-26 | 河南师范大学 | 一种3-取代喹啉类化合物的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2891544B2 (ja) * | 1994-06-16 | 1999-05-17 | ファイザー・インコーポレーテッド | ピラゾロおよびピロロピリジン類 |
| DE69736513T2 (de) * | 1996-02-07 | 2007-04-05 | Neurocrine Biosciences, Inc., San Diego | Pyrazolopyrimidine als crf rezeptor-antagonisten |
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| WO1998029397A1 (fr) | 1996-12-27 | 1998-07-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes pyrimidine a anneaux condenses et leur utilisation medicinale |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法 |
| KR20000069311A (ko) * | 1997-04-22 | 2000-11-25 | 디르크 반테 | Ｃｒｆ 길항성 퀴노- 및 퀴나졸린 |
-
1998
- 1998-09-04 NL NL1010018A patent/NL1010018C2/nl not_active IP Right Cessation
- 1998-09-07 DE DE69836678T patent/DE69836678T2/de not_active Expired - Lifetime
- 1998-09-07 JP JP51510099A patent/JP4276703B2/ja not_active Expired - Fee Related
- 1998-09-07 US US09/297,837 patent/US6350750B1/en not_active Expired - Lifetime
- 1998-09-07 CA CA002270777A patent/CA2270777C/fr not_active Expired - Fee Related
- 1998-09-07 AT AT98950008T patent/ATE348812T1/de not_active IP Right Cessation
- 1998-09-07 AU AU96241/98A patent/AU9624198A/en not_active Abandoned
- 1998-09-07 WO PCT/EP1998/005726 patent/WO1999012908A1/fr active IP Right Grant
- 1998-09-07 EP EP98950008A patent/EP0966442B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2270777A1 (fr) | 1999-03-18 |
| WO1999012908A1 (fr) | 1999-03-18 |
| JP4276703B2 (ja) | 2009-06-10 |
| AU9624198A (en) | 1999-03-29 |
| DE69836678T2 (de) | 2007-04-05 |
| ATE348812T1 (de) | 2007-01-15 |
| JP2001505226A (ja) | 2001-04-17 |
| EP0966442B1 (fr) | 2006-12-20 |
| CA2270777C (fr) | 2008-04-22 |
| DE69836678D1 (de) | 2007-02-01 |
| US6350750B1 (en) | 2002-02-26 |
| EP0966442A1 (fr) | 1999-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL1010018C2 (nl) | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. | |
| KR100256707B1 (ko) | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 | |
| KR102366670B1 (ko) | O-아미노헤테로아릴알키닐기를 함유한 화합물 및 이의 제조 방법과 용도 | |
| CN1315809C (zh) | 喹啉衍生物和其作为5－ht6配体的用途 | |
| KR0173172B1 (ko) | Crf 길항제로서의 피롤로피리미딘 | |
| US8299092B2 (en) | Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one and methods of their preparation and utilization | |
| AU2010202009A1 (en) | Quinoxaline compounds | |
| IL125076A (en) | Aza compounds, diazole cycloheptane and converted cyclooctane compounds and pharmaceutical preparations containing them | |
| FI100530B (fi) | Menetelmä substituoitujen diaminoftaali-imidien ja niiden analogien va lmistamiseksi | |
| JPH0232058A (ja) | ４―アミノ―３―カルボキシキノリン類およびナフチリジン類、製法および医薬用途 | |
| TWI781607B (zh) | 一種免疫抑制劑、其製備方法和應用 | |
| JP4199668B2 (ja) | Ｓｓｔ１アンタゴニスト活性を有するピペラジン誘導体 | |
| Snyder et al. | Synthesis of 4-Hydroxyquinolines. VIII. Some Halogen Containing 4-Aminoquinoline Derivatives1 | |
| EP0650964A1 (fr) | Dérivés de 1- 2H-1-benzopyran-2-one-8-yl -pipérazine | |
| DeWald et al. | Synthesis and Potential Antipsychotic Activity of 1H-Imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidines | |
| EP0093521B1 (fr) | Dérivés de la quinoléine | |
| US5804685A (en) | Deazapurine derivatives: a new class of CRF1 specific ligands | |
| JPS5838277A (ja) | スピロチアゾリジニルピペラジン誘導体 | |
| CS202069B2 (en) | Method of preparing 2-/4-substituted piperazine-1-yl/-4-amino-6,7-dimethoxyquinazolines | |
| JPS6229585A (ja) | エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用 | |
| CN105209461A (zh) | 咪唑并吡啶衍生物 | |
| JP4477010B2 (ja) | タンパク質チロシンホスファターゼ阻害剤としてのジアミノピロロキナゾリン化合物 | |
| Nasr et al. | Synthesis of pyrimido [5, 4-c] quinolines and related quinolines as potential antimalarials | |
| CN117486782A (zh) | 一种n-取代咔唑衍生物及其制备方法和应用 | |
| CN115340499A (zh) | Bcl-xl抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD2A | A request for search or an international type search has been filed | ||
| VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20090401 |